Evotec
Martin Augustin has over 25 years of work experience in the life science industry. Martin currently holds the position of Vice President Global Business Development, Predictive Safety at Evotec and has been with the company since 2023. Prior to their current role, Augustin worked as a Senior Director of Business Development at Evotec.
Before joining Evotec, Augustin worked at Olink Proteomics as the Director of Strategic Pharma Accounts. Martin'srole focused on utilizing Olink's high-multiplex technique to identify actionable biomarkers in the human plasma proteome.
Augustin also has extensive experience at FUJIFILM Cellular Dynamics, where they held various positions including Global Director of Sales & Business Development Europe, Director of European Sales, and Senior Key Account Manager for Central Europe.
Earlier in their career, Augustin worked at Merck Millipore as a Market Development Manager, supporting the company's global drug discovery and development sales force. Martin was responsible for providing support for large molecule bioanalysis services in various regions.
Augustin also held positions at Millipore, Ingenium Pharmaceuticals AG, Biofrontera Pharmaceuticals, Fraunhofer Institute for Toxicology and Aerosole Research, and the University of Bielefeld, where they gained in-depth scientific expertise and research experience.
Overall, Augustin's work experience spans various roles in business development, sales, and market development, showcasing their strong skills and knowledge in the life science industry.
From 1986 to 1996, Martin Augustin attended Bielefeld University. No degree or field of study was specified.
This person is not in the org chart
This person is not in any teams
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.